Exploring GW’s Label Expansion Initiatives for Epidiolex
On November 26, GW Pharmaceuticals (GWPH) announced favorable top line results from its second Phase 3 trial evaluating Epidiolex on top of a patient’s existing treatment for the reduction of convulsive seizures associated with Dravet syndrome. According to the call, GW Pharmaceuticals will be testing both a capsule formulation as well as an improved oral formulation of Epidiolex in Phase 1 trials in 2019.